Sulindac attenuates isoproterenol-induced myocardial injury: In vivo and molecular docking evidence

Le résumé fourni par la source

Objectives: Myocardial infarction (MI) arises when blood flow to a particular region of the heart is obstructed, leading to myocardial injury and characteristic electrocardiographic (ECG) abnormalities. Dysregulation of the Wnt/β-catenin signalling pathway has been implicated in post-MI cardiac remodelling. This study aimed to evaluate the cardioprotective potential of sulindac, a β-catenin inhibitor, in an isoproterenol (ISO)-induced rat model of MI. Materials and Methods: Myocardial infarction was induced in Wistar rats by subcutaneous administration of ISO. Sulindac was administered orally at doses of 2, 4, and 10 mg/kg. ECG changes, blood pressure, heart rate, oxidative stress markers, cardiac biomarkers, histopathological alterations, and β-catenin levels were evaluated. Molecular docking was performed to investigate the interaction of sulindac with tumour necrosis factor-alpha (7JRA), β-catenin (1A9U), and human interleukin-6 (1ALU) using a validated docking protocol. Results: Sulindac treatment significantly reduced heart rate, cardiac biomarkers, oxidative stress, and β-catenin levels while improving blood pressure and antioxidant enzyme activity in a dose-dependent manner. Histopathological examination demonstrated reduced inflammatory cell infiltration and myocardial fibrosis in sulindac-treated animals. Molecular docking revealed favourable interactions of sulindac with TNF-α, β-catenin, and human interleukin-6, supporting its potential multi-target activity. Conclusion: Sulindac attenuated ISO-induced myocardial injury and was associated with reduced β-catenin levels and favourable molecular docking interactions with inflammatory mediators and β-catenin. These findings suggest that sulindac may exert cardioprotective effects, potentially through modulation of the Wnt/β-catenin signalling pathway. However, further molecular studies are required to confirm the underlying mechanism and support its therapeutic potential in myocardial infarction.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.